Cancer Genetics Inc (CGIX):企業のM&A・提携動向(医療機器分野)

GlobalDataが発行した調査報告書(GDME259459D)
◆英語タイトル:Cancer Genetics Inc (CGIX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:GDME259459D
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年2月14日
◆ページ数:41
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH Microarrays, Next-Generation Sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI’s clinical services include expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers engaged in clinical trials. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cancer Genetics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cancer Genetics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cancer Genetics Inc, Medical Equipment, Deal Details 11
Asset Purchase 11
Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11
Partnerships 12
Cancer Genetics Enters into Agreement with Lantern Pharma 12
Cancer Genetics Partners with ApoCell for ApoStream 13
Cancer Genetics Partners with H3 Biomedicine 14
Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 14
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 15
Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 16
Equity Offering 16
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 16
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 18
Cancer Genetics Raises USD12 Million in Public Offering of Shares 19
Cancer Genetics Completes Public Offering Of Shares For US$46 Million 20
Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 21
Cancer Genetics Completes Underwriters’ Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 23
Cancer Genetics Completes IPO For US$7 Million 24
Cancer Genetics Inc – Key Competitors 26
Key Employees 27
Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Strategy And Business Planning 30
Feb 05, 2016: Cancer Genetics Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota 30
Financial Announcements 31
Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability 31
Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates 33
May 10, 2016: Cancer Genetics Announces 39% Revenue Increase and Provides Recent Company Highlights 35
Mar 10, 2016: Cancer Genetics Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update 36
Corporate Communications 37
Jun 27, 2016: Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance 37
Other Significant Developments 38
Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 38
Jun 02, 2016: Cancer Genetics Partners with ArcherDX to Offer Archer NGS Assays as a Sequencing Service for Biotech and Pharma 39
May 04, 2016: Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Cancer Genetics Inc, Medical Equipment, Key Facts, 2015 1
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cancer Genetics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cancer Genetics Inc, Deals By Market, 2011 to YTD 2017 9
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11
Cancer Genetics Enters into Agreement with Lantern Pharma 12
Cancer Genetics Partners with ApoCell for ApoStream 13
Cancer Genetics Partners with H3 Biomedicine 14
Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 14
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 15
Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 16
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 16
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 18
Cancer Genetics Raises USD12 Million in Public Offering of Shares 19
Cancer Genetics Completes Public Offering Of Shares For US$46 Million 20
Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 21
Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 23
Cancer Genetics Completes IPO For US$7 Million 24
Cancer Genetics Inc, Key Competitors 26
Cancer Genetics Inc, Key Employees 27
Cancer Genetics Inc, Other Locations 29
Cancer Genetics Inc, Subsidiaries 29

List of Figures
Cancer Genetics Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Cancer Genetics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cancer Genetics Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 7
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cancer Genetics Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Cancer Genetics Inc (CGIX):企業のM&A・提携動向(医療機器分野)(Cancer Genetics Inc (CGIX) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆